{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:17Z","timestamp":1789430417825,"version":"build-2803163510"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T00:00:00Z","timestamp":1586217600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2020.00107","type":"journal-article","created":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T04:39:55Z","timestamp":1586234395000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":35,"title":["Efficacy and Safety of Direct Oral Anticoagulants in Elderly Patients With Atrial Fibrillation: A Network Meta-Analysis"],"prefix":"10.3389","volume":"7","author":[{"given":"Kaisheng","family":"Deng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinqun","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shufang","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huafu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,4,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ccl.2015.12.002","article-title":"The epidemiology of atrial fibrillation and stroke","volume":"34","author":"Pistoia","year":"2016","journal-title":"Cardiol Clin."},{"key":"B2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S0002-9343(02)01236-6","article-title":"A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew\/Paisley study","volume":"113","author":"Stewart","year":"2002","journal-title":"Am J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"650","DOI":"10.7326\/M14-0538","article-title":"Association between atrial fibrillation and silent cerebral infarctions: a systematic review and meta-analysis","volume":"161","author":"Kalantarian","year":"2014","journal-title":"Ann Intern Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/j.hrthm.2012.07.026","article-title":"Atrial fibrillation and the risk of incident dementia: a meta-analysis","volume":"9","author":"Santangeli","year":"2012","journal-title":"Heart Rhythm."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2174\/1871525713666150911112526","article-title":"Atrial fibrillation: epidemiology and peculiarities in the elderly","volume":"13","author":"da Silva","year":"2015","journal-title":"Cardiovasc Hematol Agents Med Chem."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2010.02915.x","article-title":"Influence of age and health behaviors on stroke risk: lessons from longitudinal studies","volume":"58","author":"Kelly-Hayes","year":"2010","journal-title":"J Am Geriatr Soc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.117.309732","article-title":"Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes","volume":"120","author":"Staerk","year":"2017","journal-title":"Circ Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.amjmed.2007.01.026","article-title":"Atrial fibrillation in the elderly","volume":"120","author":"Fang","year":"2007","journal-title":"Am J Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood."},{"key":"B15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.23736\/S0026-4725.17.04553-4","article-title":"Direct oral anticoagulants use in elderly patients with non valvular atrial fibrillation: state of evidence","volume":"66","author":"Benedetti","year":"2018","journal-title":"Minerva Cardioangiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s11239-016-1410-z","article-title":"Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation","volume":"42","author":"Khan","year":"2016","journal-title":"J Thromb Thrombolysis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"j5058","DOI":"10.1136\/bmj.j5058","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"L\u00f3pez-L\u00f3pez","year":"2017","journal-title":"BMJ."},{"key":"B18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1161\/STROKEAHA.117.018395","article-title":"Real-world use of apixaban for stroke prevention in atrial fibrillation: a systematic review and meta-analysis","volume":"49","author":"Proietti","year":"2018","journal-title":"Stroke."},{"key":"B19","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ijcard.2015.11.084","article-title":"Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups","volume":"204","author":"Lip","year":"2016","journal-title":"Int J Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest."},{"key":"B23","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1160\/TH11-10-0690","article-title":"Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis","volume":"106","author":"Lip","year":"2011","journal-title":"Thromb Haemost."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1002\/sim.6527","article-title":"Reducing Monte Carlo error in the Bayesian estimation of risk ratios using log-binomial regression models","volume":"34","author":"Salmer\u00f3n","year":"2015","journal-title":"Stat Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3758\/s13423-016-1015-8","article-title":"A simple introduction to Markov Chain Monte-Carlo sampling","volume":"25","author":"van Ravenzwaaij","year":"2016","journal-title":"Psychon Bull Rev"},{"key":"B26","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General methods for monitoring convergence of iterative simulations","volume":"7","author":"Brooks","year":"1998","journal-title":"J Comput Graph Stat."},{"key":"B27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ."},{"key":"B28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","article-title":"Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)","volume":"130","author":"Halperin","year":"2014","journal-title":"Circulation."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1253\/circj.CJ-13-1324","article-title":"Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age","volume":"78","author":"Hori","year":"2014","journal-title":"Circ J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e003432","DOI":"10.1161\/JAHA.116.003432","article-title":"Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial","volume":"5","author":"Kato","year":"2016","journal-title":"J Am Heart Assoc."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","author":"Eikelboom","year":"2011","journal-title":"Circulation."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","article-title":"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial","volume":"35","author":"Halvorsen","year":"2014","journal-title":"Eur Heart J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrcardio.2014.118","article-title":"Global epidemiology of atrial fibrillation","volume":"11","author":"Rahman","year":"2014","journal-title":"Nat Rev Cardiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.rec.2016.11.033","article-title":"2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. Rev Esp Cardiol","volume":"70","author":"Kirchhof","year":"2017"},{"key":"B35","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jjcc.2017.08.005","article-title":"Efficacy and safety of rivaroxaban in extreme elderly patients with atrial fibrillation: analysis of the Shikoku Rivaroxaban Registry Trial (SRRT)","volume":"71","author":"Bando","year":"2018","journal-title":"J Cardiol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","article-title":"Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation","volume":"115","author":"Hylek","year":"2007","journal-title":"Circulation."},{"key":"B37","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet."},{"key":"B38","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","author":"Mant","year":"2007","journal-title":"Lancet."},{"key":"B39","first-page":"16","article-title":"Factors that affect rate of INR decline after warfarin discontinuation","volume":"114","author":"Burmester","year":"2015","journal-title":"WMJ."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3346","DOI":"10.1093\/eurheartj\/ehu367","article-title":"Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation","volume":"35","author":"Cappato","year":"2014","journal-title":"Eur Heart J."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1093\/eurheartj\/ehv177","article-title":"Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation","volume":"36","author":"Cappato","year":"2015","journal-title":"Eur Heart J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21090","article-title":"Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis","volume":"21","author":"Sterne","year":"2017","journal-title":"Health Technol Assess."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1080\/03007995.2017.1334638","article-title":"Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients","volume":"33","author":"Deitelzweig","year":"2017","journal-title":"Curr Med Res Opin."},{"key":"B44","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/phar.1905","article-title":"Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment","volume":"37","author":"Stanton","year":"2017","journal-title":"Pharmacotherapy."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e0160064","DOI":"10.1371\/journal.pone.0160064","article-title":"Comparison of the non-VKA oral anticoagulants apixaban, dabigatran, and rivaroxaban in the extended treatment and prevention of venous thromboembolism: systematic review and network meta-analysis","volume":"11","author":"Cohen","year":"2016","journal-title":"PLoS ONE."},{"key":"B46","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1182\/bloodadvances.2019000572","article-title":"Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world","volume":"3","author":"Aryal","year":"2019","journal-title":"Blood Adv."},{"key":"B47","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2174\/1389450118666171013095413","article-title":"New advances in atrial fibrillation management: the role of apixaban","volume":"19","author":"Rosano","year":"2018","journal-title":"Curr Drug Targets."},{"key":"B48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ahj.2016.06.008","article-title":"Apixaban compared with parenteral heparin and\/or vitamin K antagonist in patients with nonvalvular atrial fibrillation undergoing cardioversion: rationale and design of the EMANATE trial","volume":"179","author":"Ezekowitz","year":"2016","journal-title":"Am Heart J."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1161\/CIR.0000000000000040","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"January","year":"2014","journal-title":"Circulation."},{"key":"B50","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/S2352-3026(18)30191-1","article-title":"Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis","volume":"6","author":"Dawwas","year":"2019","journal-title":"Lancet Haematol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2146\/ajhp150821","article-title":"Edoxaban: A direct oral anticoagulant","volume":"74","author":"Poulakos","year":"2017","journal-title":"Am J Health Syst Pharm."},{"key":"B52","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40261-016-0487-7","article-title":"Cost-Effectiveness analysis of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation in Taiwan","volume":"37","author":"Liu","year":"2017","journal-title":"Clin Drug Investig."},{"key":"B53","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2147\/VHRM.S63060","article-title":"Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism","volume":"11","author":"Chan","year":"2015","journal-title":"Vasc Health Risk Manag."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/eurheartj\/eht039","article-title":"Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)","volume":"34","author":"Connolly","year":"2013","journal-title":"Eur Heart J."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1177\/1060028018771264","article-title":"Gender differences in efficacy and safety of direct oral anticoagulants in atrial fibrillation: systematic review and network meta-analysis","volume":"52","author":"Raccah","year":"2018","journal-title":"Ann Pharmacother."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00107\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T04:39:58Z","timestamp":1586234398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fmed.2020.00107\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,7]]},"references-count":55,"alternative-id":["10.3389\/fmed.2020.00107"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.00107","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,7]]},"article-number":"107"}}